We're building a better ClinicalTrials.gov. Check it out and tell us what you think!

Key Record Dates

ClinicalTrials.gov Identifier: NCT04693234
Brief Title: AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

First Submitted : December 22, 2020
First Submitted that Met QC Criteria : December 30, 2020
First Posted : January 5, 2021

Last Update Submitted that Met QC Criteria : July 27, 2022
Last Update Posted : July 28, 2022